Predicting radiation esophagitis using 18F-FDG PET during chemoradiotherapy for locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 2, 2016, Pages 213-221

  Mehmood, Qurrat ^a,b   Sun, Alexander ^a,b   Becker, Nathan ^a,b   Higgins, Jane ^a,b   Marshall, Andrea ^a,b   Le, Lisa W ^a   Vines, Douglass C ^a   McCloskey, Paula ^a,b   Ford, Victoria ^a,b   Clarke, Katy ^a,b   Yap, Mei ^a,b   Bezjak, Andrea ^a,b   Bissonnette, Jean Pierre ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

18 FDG PET; Chemoradiotherapy; Esophagitis; Non small cell lung cancer; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; PEMETREXED;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGITIS; FEMALE; HUMAN; MALE; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIAITON ESOPHAGITIS; RANK SUM TEST; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; RADIATION INJURIES;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; ESOPHAGITIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIATION INJURIES;

EID: 84958983995     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.10.006     Document Type: Article

References (25)

1. Aupérin A, Pechoux CL, Rolland E, et al. Meta-Analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181-2190.
2. ORourke N, Figuls MR, Bernado NF, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;6:CD002140.
3. Palma DA, Senan S, Oberije C, et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-Analysis. Int J Radiat Oncol Biol Phys. 2013;87:690-696.
4. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63:667-671.
5. Ozgen A, Hayran M, Kahraman F. Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung cancer patients treated with concurrent radiotherapy and chemotherapy. J Radiat Res. 2012;53:916-922.
6. Zhang Z, Xu J, Zhou T, et al. Risk factors of radiationinduced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy. Radiat Oncol. 2014;9:54.
7. Yuan ST, Brown RJK, Zhao L, et al. Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiat Oncol. 2014;9:37.
8. Aerts HJ, Van Baardwijk A, Petit SF, et al. Identification of residual metabolic-Active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91: 386-392.
9. Van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol. 2007;82:145-152.
10. Van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771-778.
11. Bradley J, Movsas B. Radiation esophagitis: Predictive factors and preventive strategies. Semin Radiat Oncol. 2004;14:280-286.
12. Feng M, Kong FM, Gross M, et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys. 2009;73:1228-1234.
13. Gillham C, Zips D, Pönisch F, et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol. 2008;88:335-341.
14. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiother Oncol. 2005;77:5-10.
15. Nijkamp J, Rossi M, Lebesque J, et al. Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol. 2013;106:118-123.
16. Bissonnette JP, Purdie TG, Higgins J, et al. Cone-beam computed tomographic image guidance for lung cancer radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73:927-934.
17. Vanderhoek M, Perlman S, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med. 2012;53:4-11.
18. Uyterlinde W, Chen C, Kwint M, et al. Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. Radiother Oncol. 2013;107:392-397.
19. Werner-Wasik M, Yorke E, Deasy J, et al. Radiation dosevolume effects in the esophagus. Int J Radiat Oncol Biol Phys. 2010;76(suppl 3):S86-S93.
20. McGinnis WL, Loprinzi C, Buskirk SJ, et al. Placebocontrolled trial of sucralfate for inhibiting radiationinduced esophagitis. J Clin Oncol. 1997;15:1239-1243.
21. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group Trial 98-01. J Clin Oncol. 2005;23: 2145-2154.
22. Bakheet S, Amin T, Alia A, et al. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med. 1999;24: 995.
23. Shrikanthan S, Aydin A, Dhurairaj T, et al. Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. Clin Nucl Med. 2005;30:695-697.
24. Bural G, Kumar R, Mavi A, et al. Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET. Clin Nucl Med. 2005;30:182-183.
25. Yap ML, Sun A, Marshall A, et al. 4D-PET/CT-based adaptive dose escalated radiotherapy (RT) in locally advanced non-small cell lung cancer (LA-NSCLC). Paper presented at: 15th World Conference on Lung Cancer. October 27-30, 2013; Sydney, Australia.